US Patent Issued to Arrowhead Pharmaceuticals on Dec. 2 for "RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use" (Wisconsin Inventors)

ALEXANDRIA, Va., Dec. 2 -- United States Patent no. 12,486,502, issued on Dec. 2, was assigned to Arrowhead Pharmaceuticals Inc. (Pasadena, Calif.).

"RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use" was invented by Anthony Nicholas (Oregon, Wis.), Erik W. Bush (Verona, Wis.), David Itiro Kasahara (Madison, Wis.) and Casi M. Schienebeck (Deerfield, Wis.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed herein inhibit...